Vitigo is a Janus kinase (JAK) inhibitor used for:
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Ruxolitinib is indeed indicated for the treatment of certain hematologic conditions. The key indications include:
Both conditions involve dysfunction in the JAK-STAT signaling pathway, which Ruxolitinib targets as a JAK inhibitor, helping to reduce symptoms, manage blood counts, and improve overall quality of life in affected patients.
It is not known if alcohol interacts with Vitigo 1.5% Cream. Please consult the doctor.
Ruxolitinib belongs to pregnancy category C. Do not take Vitigo 1.5% Cream if you are pregnant. Consult the doctor if you are pregnant, planning for pregnancy, or if you think you are pregnant.
It is not known if Ruxolitinib passes into breast milk. Avoid breastfeeding while on treatment with Vitigo 1.5% Cream and for 2 weeks after the last dose.
If you experience dizziness after taking Vitigo 1.5% Cream, avoid driving or operating heavy machinery.
Dose adjustment may be needed in patients with moderate or severe renal impairment. It may not be recommended for patients with end-stage renal disease not requiring dialysis. If you have a history of kidney problems, inform the doctor before taking Vitigo 1.5% Cream.
Dose adjustment may be needed in patients with hepatic impairment. If you have a history of liver problems, inform the doctor before taking Vitigo 1.5% Cream.
Treatment of Myelofibrosis, polycythaemia vera (PV), and graft-versus-host disease (GVHD)
Vitigo 1.5% Cream contains Ruxolitinib, a Janus-associated kinase (JAK1 and JAK2) inhibitor that reduces spleen size and alleviates symptoms like fever, bone pain, night sweats, and weight loss in patients with myelofibrosis. In polycythemia vera, it lowers red blood cell production, reducing the risk of serious blood and vascular complications. RUXOLITINIB also improves symptoms and survival in acute and chronic graft-versus-host disease.
Vitigo inhibits Janus kinase (JAK) pathways, which consist of intracellular tyrosine kinases. These kinases are involved in immune cell function and inflammation associated with conditions like atopic dermatitis. JAK inhibitors prevent the phosphorylation and activation of STATs (signal transducers and activators of transcription), reducing inflammatory signals.
Contraindicated in patients with known hypersensitivity to Ruxolitinib or any of its components.
Vitigo 1.5% Cream may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Vitigo 1.5% Cream is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Store in a cool and dry place away from sunlight
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.